Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin

NCT05031546 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Uremic Pruritus

Interventions

DRUG: Difelikefalin

Sponsor

Cara Therapeutics, Inc.